Drug Profile
QX 101
Alternative Names: QX-101Latest Information Update: 15 Mar 2007
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Cell cycle protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Mar 2007 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 14 Dec 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 22 Sep 1998 Preclinical development for Cancer in Japan (Unknown route)